Iovance Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IOVA Nasdaq 2836 www.iovance.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Iovance Biotherapeutics, Inc.

Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review - Dec 31st, 2025 9:13 am
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street - Dec 29th, 2025 7:50 am
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Dec 19th, 2025 3:15 pm
Iovance Biotherapeutics (IOVA): Is the Market Overlooking a Potential Rebound in Valuation After a Tough Year? - Dec 8th, 2025 9:09 am
Weighing Iovance Biotherapeutics After a 71.8% Slide and DCF Upside in 2025 - Dec 8th, 2025 7:08 am
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - Dec 7th, 2025 7:45 am
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? - Nov 11th, 2025 4:45 am
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y - Nov 7th, 2025 11:45 am
Is Iovance Biotherapeutics (IOVA) Undervalued? A Fresh Look at Valuation After Recent Share Price Rebound - Nov 7th, 2025 9:14 am
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street - Nov 7th, 2025 6:45 am
BC-Most Active Stocks - Nov 6th, 2025 8:30 am
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates - Nov 6th, 2025 7:15 am
Iovance Biotherapeutics: Q3 Earnings Snapshot - Nov 6th, 2025 6:19 am
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results - Nov 6th, 2025 6:00 am
Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates - Nov 5th, 2025 3:20 pm
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates - Nov 4th, 2025 4:00 pm
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline - Nov 3rd, 2025 8:00 am
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) - Nov 3rd, 2025 5:00 am
Iovance Biotherapeutics (IOVA): Exploring Valuation After a Prolonged Share Price Decline - Oct 23rd, 2025 2:12 pm
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 - Oct 23rd, 2025 2:05 pm